<DOC>
	<DOCNO>NCT01818947</DOCNO>
	<brief_summary>The purpose study understand real world gefitinib usage pattern , patient characteristic outcome present Caucasian population</brief_summary>
	<brief_title>Gefitinib Usage Outcomes Routine Treatment</brief_title>
	<detailed_description>A multicentre , retrospective chart review study characterise gefitinib usage outcomes routine treatment</detailed_description>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patients receive gefitinib first line UK Single Payment Access ( SPA ) scheme Locally advance metastatic EGFR mutation positive NSCLC Supplied first pack gefitinib prior 1st January 2012 Patient treat privately ( i.e . outside NHS ) Gefitinib secondline therapy follow treatment failure prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>epidermal growth factor receptor mutation</keyword>
	<keyword>gefitinib</keyword>
	<keyword>Iressa</keyword>
</DOC>